| Literature DB >> 27141994 |
Yanqing Gu1, Jinchun Zhou1, Qin Wang1, Weimin Fan1, Guoyong Yin1.
Abstract
Fracture healing is closely related to the number and activity of bone marrow mesenchymal stem cells (BMSCs) near the <hemical">span class="Disease">fracture site. The present study was to investigate the effect of Rg1 on osteogenic differentiation of cultured BMSCs and related mechanisms and on the fracture healing in a fracture model. In vitro experiments showed that Rg1 promoted the proliferation and osteogenic differentiation of BMSCs. Western blot analyses demonstrated that Rg1 promoted osteogenic differentiation of BMSCs through the glucocorticoid receptor (GR)-dependent BMP-2/Smad signaling pathway. In vivo, X-ray examination showed that callus growth in rats treated with Rg1 was substantially faster than that in control rats after fracture. The results of H&E and Safranin-O/Fast Green staining revealed that, compared with controls, rats in the Rg1 treatment group had a significantly higher proportion of trabecular bone but a much lower proportion of fibers and cartilage components inside the callus. Micro-CT suggested that bone mineral density (BMD), percent bone volume (BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th) were significantly increased in the treatment group, whereas trabecular separation (Tb.Sp) was significantly reduced. Thus, Rg1 promotes osteogenic differentiation by activating the GR/BMP-2 signaling pathway, enhances bone calcification, and ultimately accelerates the fracture healing in rats.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27141994 PMCID: PMC4855182 DOI: 10.1038/srep25282
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Micro-CT assessment of rat tibial fractures between the Rg1 group and the control group at 1, 2 and 3 weeks.
| 1w | 1w + Rg1 | 2w | 2w + Rg1 | 3w | 3w + Rg1 | |
|---|---|---|---|---|---|---|
| BV/TV (%) | 29.17 ± 2.281 | 36.28 ± 1.069* | 52.36 ± 1.314 | 53.91 ± 2.121* | 56.82 ± 2.077 | 64.71 ± 0.9444* |
| BS/TV (1/mm) | 2.692 ± 0.8699 | 4.416 ± 0.4582 | 4.522 ± 0.1187 | 5.316 ± 0.2950* | 5.294 ± 0.3111 | 5.792 ± 0.1764* |
| Tb.N (/mm) | 0.753 ± 0.1557 | 1.082 ± 0.029* | 1.404 ± 0.0546 | 1.643 ± 0.068* | 1.825 ± 0.073 | 2.369 ± 0.163* |
| Tb.Sp (μm) | 0.801 ± 0.1328 | 0.6556 ± 0.0534 | 0.633 ± 0.056 | 0.5136 ± 0.023* | 0.5405 ± 0.04841 | 0.4167 ± 0.069* |
| Tb.Th (μm) | 0.21 ± 0.014 | 0.3195 ± 0.041 | 0.349 ± 0.017 | 0.4478 ± 0.026* | 0.5086 ± 0.017 | 0.6412 ± 0.04* |
| BMD | 0.459 ± 0.03 | 0.726 ± 0.00853* | 0.633 ± 0.0388 | 1.681 ± 0.123* | 1.663 ± 0.09572 | 2.042 ± 0.03478* |
Sequences of primers of the genes in RT-PCR analysis.
| ALP | TCACTTCCGCCCGGAACCCT | TGTCCTGCCGGCCCAAGAGA |
| OCN | GGCAGGTGCAAAGCCCAGCG | GGGCTGGGGCTCCAAGTCCAT |
| COL1 | CTGCCCCTCGCAGGGGTTTG | GCCTGCACATGTGTGGCCGA |
| BMP-2 | TGAACACAGCTGGTCTCAGG | ACCCCACATCACTGAAGTCC |
| RUNX2 | TCACAAATCCTCCCCAAGTGG | GAATGCGCCCTAAATCACTGA |
| GAPDH | CCATCATGAAGTGTGACGTG | ACATCTGCTGGAAGGTGGAC |
| MKP-1 | CTGCTTTGATCA ACGTCTCG | AAGCTGAAGTTGGGGGAGAT |
| SGK | TGCTCTATGGCCTG CCTCCGTTC | GTCACTGGGCCCGCTCACATTTG |
Figure 1Effect of Rg1 on cell viability and apoptosis.
(A) A CCK8 assay was performed after incubation of BMSCs (2 × 104 cells/mL) with Rg1 (0.1, 1 and 10 μg/mL) or dexamethasone for 24, 48, 72 and 96 h in 96-well plates. (B) EdU staining of Rg1 and dexamethasone-treated BMSCs at day 4. EdU histogram. (C) BMSCs (1.0 × 105 cells/mL) were stimulated with or without Rg1 (0.1, 1 and 10 μg/mL) or dexamethasone for 96 h in a 6-cm culture plate. Cells were collected and stained with Annexin V and propidium iodide (PI) and then examined by flow cytometry. (D) FACS histogram. Values are expressed as the means ± S.D. of triplicate experiments. All data are representative of three independent experiments.
Figure 2Stimulatory effect of Rg1 on osteogenic differentiation of BMSCs.
(A) ALP staining of Rg1 and dexamethasone-treated BMSCs at days 7 and 14. (B) Alizarin red staining of Rg1- and dexamethasone-treated BMSCs at day 18 for the comparison of mineralization in the different groups. Values are expressed as means ± SD of triplicate experiments.*P < 0.05, **P < 0.01, ***P < 0.001.
Figure 3Effect of Rg1 on the expression of genes related to osteogenic differentiation of BMSCs.
(A) RT-PCR analysis of mRNA expression of osteogenic genes, including BMP-2, Runx2, OCN, COL1 and ALP, in BMSCs treated with Rg1 or dexamethasone for 7 or 14 days. (B) Western blot analysis of the expression of osteogenic proteins, including BMP-2, Runx2, OCN, COL1 and ALP, in BMSCs treated with Rg1 or dexamethasone for 7 or 14 days. Values are expressed as means ± SD of triplicate experiments.*P < 0.05, **P < 0.01, ***P < 0.001.
Figure 4Effect of Rg1 on the GR-dependent BMP/Smad signaling pathway.
(A) Western blot analysis of the effect of Rg1 and dexamethasone on translocation of the GR from the cytoplasm into the nucleus, (B) Immunofluorescence imaging demonstrated that Rg1 and dexamethasone promoted GR nuclear translocation. (C) C, The transcription of the responsive genes were analyzed by semi-quantitative RT-PCR. 1 μg/ml Rg1 mimicked Dex to induce the transcription of glucocorticoid-responsive genes such as MKP-1 and SGK, while RU486 could abolish the effects. (D) Western blot analysis of the effect of Rg1 and dexamethasone on the phosphorylation level of Smad1/5 and Smad2. Values are expressed as means ± SD of triplicate experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 5Effect of Rg1 on osteogenic differentiation of BMSCs after blocking translocation of the GR into the nucleus inhibiting the effect of BMP-2, transfection with shBMP-2 or transfection with shSmad1.
Western blot analysis of the effect of Rg1 on expression of the osteogenic proteins BMP-2, RUNX2, ALP, OCN and COL1 in cells treated with (A) the GR antagonist RU486 (B) the BMP-2 inhibitor noggin (C) shBMP-2 or (C) shSmad1. Values are expressed as means ± SD of triplicate experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 6Effect of Rg1 on the GR-dependent BMP/Smad signaling pathway.
Figure 7Pharmacokinetic analysis of rats administered an intraperitoneal injection of 20 mg/kg Rg1.
(A) Full mass spectrum scan of Rg1 and icariin. (B) (a) Chromatogram of plasma samples of blank control rats. (b,c) HPLC chromatogram of blank control plasma samples containing Rg1 and the icariin reference and of plasma samples of rats treated with Rg1. (C) The pharmacokinetic curve of Rg1 showing the characteristics of Rg1 in rats at each time point.
Figure 8Creation of the rat fracture model.
A fracture was created in the middle section of the tibia by the three-point bending method using an Einhorn apparatus. Stimulatory effect of Rg1 on healing of the tibial fracture. (A) X-ray examination showing the stable rat tibia fracture. (B) Comparison of X-ray images of rat tibial fractures between the Rg1 group and the control group at 7, 14 and 21 days after fracture. (C) Comparison of micro-CT images of rat tibial fractures between the Rg1 group and the control group at 7, 14 and 21 days after fracture.
Figure 9Effect of Rg1 on morphological changes in the fracture callus.
(A) H&E staining of bone sections showing morphological changes in cancellous and trabecular bone in the Rg1 and control groups at 7, 14, and 21 days after fracture. (B) Safranin-O/Light Green Red staining of bone sections showing comparison of the proportion of fibrous and osseous callus within the fracture site in Rg1 and control groups at 7, 14, and 21 days after fracture.